Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

City of Hope

Status and phase: Withdrawn; Early Phase 1

Conditions: Colon Carcinoma; Chemotherapy-Induced Peripheral Neuropathy; Breast Carcinoma

Treatments: Drug: Delta-8-Tetrahydrocannabinol; Drug: Cannabidiol; Other: Questionnaire Administration; Drug: Placebo Administration

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT05672342

NCI-2022-10253 (Registry Identifier)

P30CA033572 (U.S. NIH Grant/Contract)

22339 (Other Identifier)

R21CA260447 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This clinical trial tests how well phytocannabinoids (cannabidiol [CBD] and tetrahydrocannbinol [THC]) work in reducing chronic chemotherapy-induced peripheral neuropathy (CIPN) in breast and colon cancer survivors. Neuropathy is the most common neurological symptom reported by cancer patients due to treatment. A variety of pharmacologic treatments have been evaluated to alleviate CIPN symptoms; however, no definitive treatment has been found to successfully treat all the symptoms of CIPN. Therefore, investigators continue to seek other possible treatment options including cannabis. Phytocannabinoids may be a particularly useful intervention for cancer patients given the limited effective treatments for CIPN. In addition, cannabis-based medicines have become tremendously popular as both cancer patients and clinicians are seeking therapies with fewer potential risks of dependency and other side effects. This trial is being done to provide cancer patients and clinicians with reliable information to help guide their use of phytocannabinoids to manage the tremendous distress and pain experienced by many cancer patients, which impacts their long-term quality of life.

Full description

PRIMARY OBJECTIVE:

I. Assess the ability of CBD and THC:CBD to reduce CIPN symptoms as compared to placebo using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group (FACT/GOG)-Neurotoxicity (Ntx) subscale among breast and colon cancer survivors.

SECONDARY OBJECTIVES:

I. Evaluate the impact of CBD and THC:CBD as compared to placebo on quality of life using the Functional Assessment of Cancer Therapy General (FACT-G) among breast and colon cancer survivors with chronic CIPN.

II. Document the utilization of neuropathic and pain medications by cancer patients with chronic CIPN during treatment with CBD and THC:CBD as compared to placebo.

III. Describe the side effects of CBD and THC:CBD treatment.

EXPLORATORY OBJECTIVES:

I. Assess neurological symptoms and function with the Neuropathy Pain Scale (NPS), Total Neuropathy Sccore - clinically based (TNSc), quantitative sensory testing (QST), Grooved Pegboard Test (GPT), and Unipedal Stance balance test (USBT) among patients with chronic CIPN treated with CBD and THC:CBD as compared to placebo.

II. Evaluate for predictors of response to CBD and THC:CBD for chronic CIPN.

OUTLINE: This is a dose-escalation study of CBD and THC. Patients are randomized to 1 of 3 arms.

ARM I: Patients receive CBD orally (PO) on study.

ARM II: Patients receive CBD PO + THC PO on study.

ARM III: Patients receive placebo PO on study.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Documented informed consent of the participant and/or legally authorized representative

  • Assent, when appropriate, will be obtained per institutional guidelines

• Agreement to allow the use of archival tissue from diagnostic tumor biopsies

  • If unavailable, exceptions may be granted with study principal investigator (PI) approval

• Willingness to comply with all study interventions including the use of medical cannabis and follow-up assessments

• Age: >= 18 years

• Eastern Cooperative Oncology Group (ECOG) =< 2

• Ability to read and understand English for questionnaires

• Patients must have either neuropathy >= 1 according to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 scale or a neuropathy score of > 3 on a 0-10 scale plus a FACT/GOG-Ntx score of > 10

• The patient's previous chemotherapy treatment must have included a taxane (paclitaxel, nab-paclitaxel, or docetaxel) or platinum (cisplatin, oxaliplatin, or carboplatin) and considered the primary cause of the neuropathy by the medical team

• Total bilirubin =< 1.5 x upper limit of normal (ULN) (unless has Gilbert's disease)

• Aspartate aminotransferase (AST) =< 3 x ULN

• Alanine aminotransferase (ALT) =< 3 x ULN

• Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

• Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 1 months after the last dose of protocol therapy

  • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

• Current active treatment with chemotherapy, radiation or surgery in the past 3 months or planned treatment during this study protocol period. Note: Hormonal therapy is allowed

Exclusion criteria

• Concurrent use of other alternative medicines such as medical cannabis, herbal agents and high dose vitamins and minerals

• Liver cirrhosis Child-Pugh B or C

• Mental incapacitation or significant emotional or psychological disorder that, in the opinion of the investigators, precludes study entry (These patients may not be able to cooperate with this slightly invasive procedure or with the data collection process)

• History of diabetic neuropathy, neuropathy related to human immunodeficiency virus (HIV), or other medical causes of chronic neuropathy in the baseline assessment including past medical history, any history of diabetes, alcoholism, and vitamin B deficiency

• Previous medical cannabis use for any indication within 30 days of enrollment

• Planned or actual changes in type of medications that could affect symptoms related to CIPN. New medications for the treatment of CIPN are not allowed during the study.

  • Note: Subjects need to be on stable doses of CIPN medications for 4 weeks

• Strong inhibitors or inducers of CYP3A4

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent

• Clinically significant uncontrolled illness

• Diagnosis of Gilbert's disease

• Females only: Pregnant or breastfeeding

• Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures

• Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

0 participants in 3 patient groups, including a placebo group

Arm I (CBD)

Experimental group

Description:

Patients receive CBD PO on study.

Treatment:

Other: Questionnaire Administration

Drug: Cannabidiol

Arm II (CBD + THC)

Experimental group

Description:

Patients receive CBD PO + THC PO on study.

Treatment:

Other: Questionnaire Administration

Drug: Cannabidiol

Drug: Delta-8-Tetrahydrocannabinol

Arm III (placebo)

Placebo Comparator group

Description:

Patients receive placebo PO on study.

Treatment:

Other: Questionnaire Administration

Drug: Placebo Administration